Blue Earth Diagnostics Announces Key Results from Phase 3 SPOTLIGHT Study of 18F-rhPSMA-7.3, an Investigational PET Imaging Agent, in Biochemical Recurrence of Prostate Cancer
Retrieved on:
Tuesday, February 15, 2022
Research, Clinical Trials, Biotechnology, Radiology, Health, General Health, Other Science, Science, Oncology, Patient, PET, Carboxypeptidase, Man, Recurrence, Prostate cancer, DRS, Membrane, Safety, PSA, Radiopharmaceutical, RH, Lymph, Multimedia, Prostatectomy, ASCO, Medical imaging, Radiohybrid Prostate-Specific Membrane Antigen (rhPSMA), Blue Earth Diagnostics, Bracco Imaging, RADIOHYBRID PROSTATE-SPECIFIC MEMBRANE ANTIGEN (RHPSMA), BLUE EARTH DIAGNOSTICS, BRACCO IMAGING
General use: This 18F-rhPSMA-7.3 PET image shows prostate cancer spread beyond the prostate region.
Key Points:
- General use: This 18F-rhPSMA-7.3 PET image shows prostate cancer spread beyond the prostate region.
- Technical use: This 18F-rhPSMA-7.3 PET image shows detection of recurrent prostate cancer in several retroperitoneal lymph nodes, as indicated by the green arrows.
- Based on the majority read results from the three blinded, independent PET readers, the overall detection rate (DR) of 18F-rhPSMA-7.3 PET in the SPOTLIGHT study was 83% (322/389).
- The Phase 3 SPOTLIGHT study investigated the diagnostic performance of 18F-rhPSMA-7.3 PET imaging as a potential decision-making aid in assessing suspected biochemical recurrence of the disease.